Jim Simons Avenue Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$0.22 - $0.56 $27,368 - $69,664	124,400 New	124,400 $34,000
Q4 2021 Feb 11, 2022	SELL	$0.88 - $1.78 $103,928 - $210,218	-118,100 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$1.48 - $2.65 $58,883 - $105,432	39,786 Added 50.8%	118,100 $176,000
Q2 2021 Aug 13, 2021	BUY	$2.41 - $7.11 $188,736 - $556,812	78,314 New	78,314 $197,000
Q4 2020 Feb 10, 2021	SELL	$2.95 - $11.04 $224,025 - $838,388	-75,941 Closed	0 $0

Q3 2020 Nov 13, 2020	SELL	$9.37 - $12.06 $448,092 - $576,733	-47,822 Reduced 38.64%	75,941 $822,000
Q2 2020 Aug 13, 2020	BUY	$8.29 - $11.47 $472,762 - $654,111	57,028 Added 85.45%	123,763 $1.33 Million
Q1 2020 May 14, 2020	BUY	$6.44 - $11.32 $348,932 - $613,340	54,182 Added 431.63%	66,735 $597,000
Q4 2019 Feb 13, 2020	BUY	$5.26 - $9.6 $66,028 - $120,508	12,553 New	12,553 $121,000
Q3 2019 Nov 13, 2019	SELL	$5.58 - $6.3 $89,838 - $101,430	-16,100 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$4.33 - $6.54 $22,914 - $34,609	5,292 Added 48.96%	16,100 $101,000
Q1 2019 May 14, 2019	BUY	$4.75 - $6.59 $51,338 - $71,224	10,808 New	10,808 $51,000

Ticker ATXI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,127,720
Market Cap $14.1M
Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was in...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.